Benzoyl peroxide/tretinoin - Sol-Gel Technologies

Drug Profile

Benzoyl peroxide/tretinoin - Sol-Gel Technologies

Alternative Names: S6G5T 1/S6G5T 3; TWIN

Latest Information Update: 09 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Sol-Gel Technologies
  • Developer Accelovance; Sol-Gel Technologies
  • Class Anti-infectives; Antiacnes; Benzoic acids; Keratolytics; Oxidants; Retinoids; Small molecules
  • Mechanism of Action Protein synthesis inhibitors; Retinoic acid receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Acne vulgaris

Most Recent Events

  • 26 Mar 2018 Sol-Gel Technologies plan for a end-of-phase II meeting with the US FDA in the first half of 2018
  • 26 Mar 2018 Sol-Gel Technologies plans pivotal phase III trials for Acne vulgaris in USA in second half of 2018
  • 01 Oct 2017 Sol-Gel Technologies completes a phase II trial in Acne vulgaris (In children, In adolescents, In adults, In the elderly) in USA (Topical) (NCT02661958)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top